Condition: Alopecia Areata · Sponsor: Sun Pharmaceutical Industries, Inc.
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clinical trial may participate in this study.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Service de Dermatologie CHRU de Brest - Hopital Morvan | Brest, Finistere, France | — |
| Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2 | Nice, Provence-Alpes-Côte d'Azur Region, France | — |
| CHU de Bordeaux, Hopital Saint-Andre | Bordeaux, France | — |
| Hopital Saint-Louis - GH De La Rochelle-Re-Aunis | La Rochelle, France | — |
| Hôpital La Timone-Dermatologie | Marseille, France | — |
| Hopital de l'Hotel Dieu - CHU de Nantes | Nantes, France | — |
| Hôpital Saint Louis, Centre de Santé Sabouraud | Paris, France | — |
| Centre Hospitalier Universitaire de Toulouse - Hopital Larrey | Toulouse, France | — |
| Universitätsklinikum Tübingen Universitäts-Hautklinik | Tübingen, Baden-Wüttermberg, Germany | — |
| Universitätsklinikum Erlangen, Hautklinik | Erlangen, Bavaria, Germany | — |
| Klinikum Rechts der Isar, Technische Universität München, Hautklinik | München, Bavaria, Germany | — |
| Klinik für Dermatologie, Venerologie und Allergologie | Frankfurt am Main, Hesse, Germany | — |
+ 27 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.